RSPO3 rearrangements in advanced colorectal cancer patients and their relationship with disease characteristics

Table 1 Clinical and pathological characteristics of advanced colorectal cancer (pT4a-b) patients with (n = 6) and without (n = 67) protein tyrosine phosphatase receptor type k and R-spondin 3 fusion at diagnosis, n (%)

Variable	PTPRK::RSPO3 fusion, yes (n = 6)	PTPRK::RSPO3 fusion, no (n = 67)	P value	Total (n = 73)
Age (years)1	71 (62-90)	67 (36-94)	NS	73 (36-94)
Gender
Female	3 (50)	32 (48)	NS	35 (52)
Male	3 (50)	35 (52)		38 (48)
Site of primary tumor
Right colon	3 (50)	24 (36)	0.01	27 (37)
Transverse colon	2 (33)	3 (4)		5 (7)
Left colon	0 (0)	35 (52)		35 (48)
Rectum	1 (17)	5 (8)		6 (8)
Histopathological grade
Low	5 (83)	59 (88)	NS	64 (86)
High	1 (17)	8 (12)		9 (14)
Lymph node involvement
pN0	2 (33)	28 (42)		29 (40)
pN1	3 (50)	22 (32)	NS	25 (35)
pN2	1 (17)	17 (26)		18 (25)
Metastasis status
M0	3 (50)	47 (70)	NS	50 (68)
M1	3 (50)	20 (30)		23 (32)
Size (cm)
< 5	5 (83)	39 (58)	0.08	44 (60)
≥ 5	1 (17)	28 (42)	NS	29 (40)
Microsatellite instability
Yes	0 (0)	10 (15)	0.008	10 (14)
No	6 (100)	57 (85)		63 (86)
CEA serum levels (ng/mL)1	5.7 (0.7-23)	25 (0.6-825)	0.009	23 (0.6-825)
Number of deaths	5 (83)	41 (61)	0.04	46 (63)
OS (months)1	42 (3-53)	52 (2-133)	0.002	62 (2-133)

¹Results expressed as median (range).

CEA: Carcinoembryonic antigen; OS: Overall survival; NS: Not significant.